Welcome to OM Pharma
Doxiproct® : Antihaemorrhoidal - Haemorrhoids
  Philosophy
  History
  Worldwide activity
  R & D
  Manufacturing
  Products
    Marketing Authorizations
    International Availability
    Main Products
    - Broncho-Vaxom
    - Dicynone
    - Doxium
    - Uro-Vaxom
  Other Products
    - Doxiproct
    - Doxiproct Plus
    - Gynazole
    - Sinomarin
  Health and Diseases
  News
  Contacts
  Careers and jobs
  Forum


  homepage > products > other pharma products doxiproct > limitations for use
   
 
Doxiproct
 
Limitations for use

Contraindications
Hypersensitivity towards the components of Doxiproct®.
Children under 14 years.

Precautions
In case of renal insufficiency, Doxiproct® should not be used during long periods.
Avoid long-lasting treatments.
In case of blood in the faeces or its suspected presence, as well as of a simultaneous occurrence of pain and fever, the physician must be consulted.

Pregnancy and lactation
Studies in pregnant women or animals are not available and it is not known whether calcium dobesilate crosses the placental barrier in humans. On the other hand, after topic administration, lidocaine hydrochloride is resorbed in variable quantities and can have systemic effects. Moreover, it crosses the placental barrier. In these conditions, Doxiproct® should be administered during pregnancy only if necessary.
After oral administration, calcium dobesilate is excreted into the maternal milk in low amounts, but it is not known whether this is the case with local use. After topic administration, lidocaine hydrochloride is excreted into the maternal milk. As a precaution, it should be decided between discontinuating the treatment or the breast-feeding.

  Contact us   back home